NTRK2
ENSG00000148053
Target class
Kinase
Chromosome
9
Approved drugs
5
Clinical candidates (approved and in development)
13
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- Yes
- Other names
- TRKB
- Target name
- NTRK2
- Gene name
- Neurotrophic receptor tyrosine kinase 2
- Gene symbol
- NTRK2
- Protein name
- BDNF/NT-3 growth factors receptor (EC 2.7.10.1) (GP145-TrkB) (Trk-B) (Neurotrophic tyrosine kinase receptor type 2) (TrkB tyrosine kinase) (Tropomyosin-related kinase B)
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|I-set domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 45
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 79.51
- Tissue specificity (Gini)
- 0.659
- Tissue specificity (tau)
- 0.796
- KEGG gene identifiers
- hsa:4915
- Protein interaction confidence
- 0.835296
- Protein interaction partners
- 81
- R-HSA-1257604
- R-HSA-187024
- R-HSA-2219530
- R-HSA-6811558
- R-HSA-9024909
- R-HSA-9025046
- R-HSA-9026357
- R-HSA-9026519
- R-HSA-9026527
- R-HSA-9028335
- R-HSA-9028731
- R-HSA-9032500
- R-HSA-9032759
- R-HSA-9032845
- End position
- 85095751
- Start position
- 84668375
- Chromosome
- 9
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Endosome membrane
- Single-pass type I membrane protein . Early endosome membrane . Cell projection, axon . Cell projection, dendrite . Cytoplasm, perinuclear region . Postsynaptic density . Note=Internalized to endosomes upon ligand-binding. .
- Plasma membrane
Publication evidence
- PubMed 15494731
- Tissue specificity (tau)
- 0.795659
- Expression inequality (Gini)
- 0.659255
Expression in transcripts per million
- Brain - Anterior cingulate cortex (BA24)
- 79.51
- Brain - Frontal Cortex (BA9)
- 75.02
- Brain - Cortex
- 74.24
- Brain - Caudate (basal ganglia)
- 73
- Brain - Amygdala
- 72.96
Expression in transcripts per million
- Brain - Anterior cingulate cortex (BA24)79.51
- Brain - Frontal Cortex (BA9)75.02
- Brain - Cortex74.24
- Brain - Caudate (basal ganglia)73
- Brain - Amygdala72.96
- Brain - Nucleus accumbens (basal ganglia)66.64
- Brain - Putamen (basal ganglia)58.15
- Brain - Hypothalamus40.59
- Brain - Hippocampus40.27
- Artery - Tibial37.53
- Brain - Substantia nigra37.53
- Thyroid35.22
- Nerve - Tibial28.31
- Adipose - Subcutaneous24.58
- Brain - Cerebellar Hemisphere22.29
- Artery - Coronary22.03
- Brain - Cerebellum20.3
- Breast - Mammary Tissue15.23
- Brain - Spinal cord (cervical c-1)14.29
- Vagina8.29
- Kidney - Medulla7.42
- Adipose - Visceral (Omentum)7.09
- Cervix - Ectocervix6.54
- Skin - Sun Exposed (Lower leg)5.83
- Minor Salivary Gland5.71
And 29 more, listed on the interactive page.
- GO:0031547
- GO:0051897
- GO:1902430
- GO:0005886
- GO:0043235
- GO:0002020
- GO:0004713
- GO:0005515
- GO:0043121
- GO:0060175
Related records
Trials (125)
- A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
- A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
- A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
- A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
- A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
- A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
- A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
- A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
- A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
- A Study of DCC-2701 in Participants With Advanced Solid Tumors
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Drugs (14)
- Altiratinib Neurotrophic tyrosine kinase receptor inhibitor
- AZD-6918 Neurotrophic tyrosine kinase receptor inhibitor
- AZD-7451 Neurotrophic tyrosine kinase receptor type 2 inhibitor
- Cenegermin Neurotrophic tyrosine kinase receptor agonist
- CEP-2563 Neurotrophic tyrosine kinase receptor inhibitor
- Cep-2563 dihydrochloride Neurotrophic tyrosine kinase receptor inhibitor
- Entrectinib Neurotrophic tyrosine kinase receptor inhibitor
- Larotrectinib Neurotrophic tyrosine kinase receptor inhibitor
- Larotrectinib sulfate Neurotrophic tyrosine kinase receptor inhibitor
- Lestaurtinib Neurotrophic tyrosine kinase receptor type 2 inhibitor
- PLX-7486 Neurotrophic tyrosine kinase receptor type 2 inhibitor
- Repotrectinib Neurotrophic tyrosine kinase receptor type 2 inhibitor
- Selitrectinib Neurotrophic tyrosine kinase receptor inhibitor
- Taletrectinib Neurotrophic tyrosine kinase receptor inhibitor